Key Points
- EVP Kelly Huller sold 20,000 shares of Globus Medical on Feb. 25 at an average price of $94.50 for about $1.89 million, after selling 10,000 shares on Feb. 12 at $87.67 (≈$876,700).
- Globus beat quarterly estimates, reporting $1.28 EPS versus $1.06 expected and revenue of $826.42M (vs. $803.29M), with revenue up 25.7% year‑over‑year.
- Market context: GMED has a $12.77B market cap, a 1‑year range of $51.79–$101.40, high institutional ownership (95.16%), and a consensus "Moderate Buy" target of $104.36 amid recent analyst price‑target upgrades.
Globus Medical, Inc. (NYSE:GMED - Get Free Report) EVP Kelly Huller sold 20,000 shares of Globus Medical stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total transaction of $1,890,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
Kelly Huller also recently made the following trade(s):
- On Thursday, February 12th, Kelly Huller sold 10,000 shares of Globus Medical stock. The shares were sold at an average price of $87.67, for a total transaction of $876,700.00.
Globus Medical Stock Performance
Shares of GMED stock opened at $95.39 on Friday. The stock's 50-day moving average is $90.69 and its two-hundred day moving average is $76.38. The firm has a market cap of $12.77 billion, a price-to-earnings ratio of 24.21, a PEG ratio of 2.24 and a beta of 1.06. Globus Medical, Inc. has a 1 year low of $51.79 and a 1 year high of $101.40.
Globus Medical (NYSE:GMED - Get Free Report) last posted its earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, beating the consensus estimate of $1.06 by $0.22. The business had revenue of $826.42 million during the quarter, compared to the consensus estimate of $803.29 million. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The business's quarterly revenue was up 25.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.84 EPS. As a group, research analysts predict that Globus Medical, Inc. will post 3.44 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of GMED. AQR Capital Management LLC lifted its holdings in Globus Medical by 45.9% in the first quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company's stock valued at $1,622,000 after acquiring an additional 7,086 shares during the period. Integrated Wealth Concepts LLC increased its holdings in shares of Globus Medical by 33.0% in the 1st quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company's stock valued at $320,000 after purchasing an additional 1,085 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Globus Medical by 38.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company's stock valued at $2,228,000 after purchasing an additional 8,540 shares during the period. Jones Financial Companies Lllp boosted its holdings in Globus Medical by 237.3% during the first quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company's stock worth $62,000 after buying an additional 598 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Globus Medical by 8.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company's stock worth $25,439,000 after buying an additional 28,027 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on GMED. Canaccord Genuity Group raised their target price on shares of Globus Medical from $105.00 to $112.00 and gave the stock a "buy" rating in a research report on Friday, January 9th. Barclays lifted their price objective on shares of Globus Medical from $118.00 to $123.00 and gave the company an "overweight" rating in a research note on Wednesday. Piper Sandler reiterated an "overweight" rating and set a $115.00 target price (up from $90.00) on shares of Globus Medical in a research note on Thursday, January 8th. Wells Fargo & Company raised their price target on Globus Medical from $98.00 to $104.00 and gave the stock an "overweight" rating in a report on Thursday. Finally, Wall Street Zen upgraded Globus Medical from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 3rd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Globus Medical currently has a consensus rating of "Moderate Buy" and a consensus target price of $104.36.
Read Our Latest Stock Report on GMED
About Globus Medical
(
Get Free Report)
Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.
In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
